Egypt · Delayed Price · Currency is EGP Ibnsina Pharma Statistics
Total Valuation
Ibnsina Pharma has a market cap or net worth of EGP 11.53 billion. The enterprise value is 37.71 billion.
| Market Cap | 11.53B |
| Enterprise Value | 37.71B |
Important Dates
The next estimated earnings date is Thursday, August 13, 2026.
| Earnings Date | Aug 13, 2026 |
| Ex-Dividend Date | Apr 27, 2026 |
Share Statistics
Ibnsina Pharma has 1.01 billion shares outstanding.
| Current Share Class | 1.01B |
| Shares Outstanding | 1.01B |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 26.01% |
| Owned by Institutions (%) | 24.14% |
| Float | 652.98M |
Valuation Ratios
The trailing PE ratio is 13.88 and the forward PE ratio is 9.45. Ibnsina Pharma's PEG ratio is 0.29.
| PE Ratio | 13.88 |
| Forward PE | 9.45 |
| PS Ratio | 0.14 |
| PB Ratio | 4.00 |
| P/TBV Ratio | 4.35 |
| P/FCF Ratio | 12.48 |
| P/OCF Ratio | 6.01 |
| PEG Ratio | 0.29 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 9.98, with an EV/FCF ratio of 40.82.
| EV / Earnings | 45.38 |
| EV / Sales | 0.47 |
| EV / EBITDA | 9.98 |
| EV / EBIT | 10.94 |
| EV / FCF | 40.82 |
Financial Position
The company has a current ratio of 1.03, with a Debt / Equity ratio of 9.50.
| Current Ratio | 1.03 |
| Quick Ratio | 0.67 |
| Debt / Equity | 9.50 |
| Debt / EBITDA | 7.24 |
| Debt / FCF | 29.63 |
| Interest Coverage | 1.42 |
Financial Efficiency
Return on equity (ROE) is 40.56% and return on invested capital (ROIC) is 10.53%.
| Return on Equity (ROE) | 40.56% |
| Return on Assets (ROA) | 6.00% |
| Return on Invested Capital (ROIC) | 10.53% |
| Return on Capital Employed (ROCE) | 70.07% |
| Weighted Average Cost of Capital (WACC) | 7.85% |
| Revenue Per Employee | 14.56M |
| Profits Per Employee | 151,107 |
| Employee Count | 5,500 |
| Asset Turnover | 2.23 |
| Inventory Turnover | 8.10 |
Taxes
In the past 12 months, Ibnsina Pharma has paid 141.80 million in taxes.
| Income Tax | 141.80M |
| Effective Tax Rate | 12.14% |
Stock Price Statistics
The stock price has increased by +21.06% in the last 52 weeks. The beta is 0.69, so Ibnsina Pharma's price volatility has been lower than the market average.
| Beta (5Y) | 0.69 |
| 52-Week Price Change | +21.06% |
| 50-Day Moving Average | 11.15 |
| 200-Day Moving Average | 11.12 |
| Relative Strength Index (RSI) | 45.69 |
| Average Volume (20 Days) | 11,075,895 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Ibnsina Pharma had revenue of EGP 80.05 billion and earned 831.09 million in profits. Earnings per share was 0.82.
| Revenue | 80.05B |
| Gross Profit | 6.66B |
| Operating Income | 3.45B |
| Pretax Income | 1.17B |
| Net Income | 831.09M |
| EBITDA | 3.63B |
| EBIT | 3.45B |
| Earnings Per Share (EPS) | 0.82 |
Balance Sheet
The company has 1.19 billion in cash and 27.37 billion in debt, with a net cash position of -26.18 billion or -25.97 per share.
| Cash & Cash Equivalents | 1.19B |
| Total Debt | 27.37B |
| Net Cash | -26.18B |
| Net Cash Per Share | -25.97 |
| Equity (Book Value) | 2.88B |
| Book Value Per Share | 2.86 |
| Working Capital | 935.35M |
Cash Flow
In the last 12 months, operating cash flow was 1.92 billion and capital expenditures -993.56 million, giving a free cash flow of 923.88 million.
| Operating Cash Flow | 1.92B |
| Capital Expenditures | -993.56M |
| Depreciation & Amortization | 179.53M |
| Net Borrowing | -1.14B |
| Free Cash Flow | 923.88M |
| FCF Per Share | 0.92 |
Margins
Gross margin is 8.32%, with operating and profit margins of 4.31% and 1.28%.
| Gross Margin | 8.32% |
| Operating Margin | 4.31% |
| Pretax Margin | 1.46% |
| Profit Margin | 1.28% |
| EBITDA Margin | 4.53% |
| EBIT Margin | 4.31% |
| FCF Margin | 1.15% |
Dividends & Yields
This stock pays an annual dividend of 0.16, which amounts to a dividend yield of 1.40%.
| Dividend Per Share | 0.16 |
| Dividend Yield | 1.40% |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | 4 |
| Payout Ratio | 19.26% |
| Buyback Yield | n/a |
| Shareholder Yield | 1.40% |
| Earnings Yield | 7.21% |
| FCF Yield | 8.01% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Analyst Forecast
The average price target for Ibnsina Pharma is 17.26, which is 50.87% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | 17.26 |
| Price Target Difference | 50.87% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 3 |
| Revenue Growth Forecast (3Y) | 14.63% |
| EPS Growth Forecast (3Y) | n/a |
Stock Splits
The last stock split was on June 1, 2022. It was a forward split with a ratio of 1.16666.
| Last Split Date | Jun 1, 2022 |
| Split Type | Forward |
| Split Ratio | 1.16666 |
Scores
Ibnsina Pharma has an Altman Z-Score of 2.63 and a Piotroski F-Score of 6. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 2.63 |
| Piotroski F-Score | 6 |